Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Tolerability of GS-0201 Alone and in Combination With Sacituzumab Govitecan in Advanced Solid Tumors
NCT06167317Phase 1Recruiting
- Sponsor
- Gilead Sciences
- Start
- Jan 2024
- Primary completion
- Sep 2028
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of GS-0201 in solid tumor, breast cancer, triple-negative breast cancer (TNBC) and 1 more (6 arms), sponsored by Gilead Sciences. Primary endpoints: Dose Limiting Toxicities up to 109 weeks, Adverse Events and Serious Adverse Events up to 109 weeks and 1 more. Started Jan 2024; status: recruiting.
02
Drugs
GS-0201
03
Conditions
solid tumorbreast cancertriple-negative breast cancer (TNBC)endometrial cancer (EC)
Beyond the preview
Go deeper on NCT06167317.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06167317.